NASDAQ:GILD
76.42
0.34
(0.44%)
Gilead Sciences is an American biopharmaceutical company that discovers, develops and commercializes drugs.
More at Wikipedia
Gilead Sciences Inc.
GILD-Q
Analysis and Opinions about GILD-Q
Signal
Opinion
Expert
COMMENT
COMMENT
March 20, 2020
US Healthcare? Healthcare generally under-preforms in election years. A safer pick would be GILD, for their COVID-19 research and HIV drugs.
Show full opinionHide full opinion
US Healthcare? Healthcare generally under-preforms in election years. A safer pick would be GILD, for their COVID-19 research and HIV drugs.
COMMENT
COMMENT
March 20, 2020
US Healthcare? Healthcare generally under-preforms in election years. A safer pick would be GILD, for their COVID-19 research and HIV drugs.
Show full opinionHide full opinionUS Healthcare? Healthcare generally under-preforms in election years. A safer pick would be GILD, for their COVID-19 research and HIV drugs.
TOP PICK
TOP PICK
March 11, 2020
He likes the yield. He believes they are making some headway on a CVT-19 drug on trial in China. They are also doing more M&A to bring innovation into their pipeline. They are working on liver disease drugs and HIV drugs. They have a clean balance sheet as well. Yield 3.68% (Analysts’ price target is $75.22)
He likes the yield. He believes they are making some headway on a CVT-19 drug on trial in China. They are also doing more M&A to bring innovation into their pipeline. They are working on liver disease drugs and HIV drugs. They have a clean balance sheet as well. Yield 3.68% (Analysts’ price target is $75.22)
DON'T BUY
DON'T BUY
February 25, 2020
It's a little speculative, because they could invent the coronavirus vaccine. In the past they found the hepatitis C cure. Gilead did very well until a few years ago. Now, their earnings and stock are half of their historic peak.
Show full opinionHide full opinionIt's a little speculative, because they could invent the coronavirus vaccine. In the past they found the hepatitis C cure. Gilead did very well until a few years ago. Now, their earnings and stock are half of their historic peak.
DON'T BUY
DON'T BUY
January 30, 2020
It is less of a diversified company than big pharma. He is not big on investment in this sector. It is a tough place to be. It would be better at a lower price.
Show full opinionHide full opinionIt is less of a diversified company than big pharma. He is not big on investment in this sector. It is a tough place to be. It would be better at a lower price.
DON'T BUY
DON'T BUY
January 17, 2020
Very disappointing. The update from the new CEO wasn't particularly exciting. Their HIV prep drugs is doing well. However with the Hepatitis C drug coming off patent, they have lost revenues. Deep value but they need to execute. They like the high yield with great premiums on the options. He would rather own another diversified biotech or a basket.
Show full opinionHide full opinionVery disappointing. The update from the new CEO wasn't particularly exciting. Their HIV prep drugs is doing well. However with the Hepatitis C drug coming off patent, they have lost revenues. Deep value but they need to execute. They like the high yield with great premiums on the options. He would rather own another diversified biotech or a basket.
HOLD
HOLD
August 27, 2019
A drug company that was the poster boy for high prices for drugs including hep-C creating some bad sentiment. The company has a good pipeline on HIV drugs. It trades at less than 9 times earnings. The worst is behind them. Yield 4%
Show full opinionHide full opinionA drug company that was the poster boy for high prices for drugs including hep-C creating some bad sentiment. The company has a good pipeline on HIV drugs. It trades at less than 9 times earnings. The worst is behind them. Yield 4%
DON'T BUY
DON'T BUY
August 22, 2019
It has been a bit of a value trap for years. They were effective in the cure for HEP-C. For them it has been a declining revenue steam. They made an acquisition that did not work out. Revenues have dropped 40% over the last 5 years. He would stay clear of it.
It has been a bit of a value trap for years. They were effective in the cure for HEP-C. For them it has been a declining revenue steam. They made an acquisition that did not work out. Revenues have dropped 40% over the last 5 years. He would stay clear of it.
BUY
BUY
July 17, 2019
It's been painful as it consolidates for the past 18 months. They have a hepatitis franchise, an expensive drug, that came off patent. Gilead failed to reinvest those profits, too. Their HIV franichise is doing very well. They acquired some companies, which look promising. The CEO is doing a good job. They are trading 9.5x fowarding earnings. Great dividend yield and balance sheet.
Show full opinionHide full opinionIt's been painful as it consolidates for the past 18 months. They have a hepatitis franchise, an expensive drug, that came off patent. Gilead failed to reinvest those profits, too. Their HIV franichise is doing very well. They acquired some companies, which look promising. The CEO is doing a good job. They are trading 9.5x fowarding earnings. Great dividend yield and balance sheet.
PAST TOP PICK
PAST TOP PICK
May 29, 2019
(A Top Pick Jun 27/18, Down 5%) An analyst just issued a sell report on them -- calling for a 10% downturn. It trades about 8.5 times earnings. They were victims of their success in hepatitis medicine as it cured too many people, he says. It pays a 4% yield.
Show full opinionHide full opinion(A Top Pick Jun 27/18, Down 5%) An analyst just issued a sell report on them -- calling for a 10% downturn. It trades about 8.5 times earnings. They were victims of their success in hepatitis medicine as it cured too many people, he says. It pays a 4% yield.
BUY
BUY
May 3, 2019
Value trap for so long for so many. Cure for Hep C had generated huge cash flow. HIV franchise is leading the pack. Yesterday's numbers are fantastic. Likes that they've diversified their assets. New CEO gave realistic guidance. Likes it at these levels.
Show full opinionHide full opinionValue trap for so long for so many. Cure for Hep C had generated huge cash flow. HIV franchise is leading the pack. Yesterday's numbers are fantastic. Likes that they've diversified their assets. New CEO gave realistic guidance. Likes it at these levels.
N/A
N/A
March 14, 2019
The pharmaceuticals and the health technology are not his skill set. The balance sheet is OK for a pharmaceutical. The analyst community seems to like it. (Analysts’ price target is $80.70)
Show full opinionHide full opinionThe pharmaceuticals and the health technology are not his skill set. The balance sheet is OK for a pharmaceutical. The analyst community seems to like it. (Analysts’ price target is $80.70)
HOLD
HOLD
March 13, 2019
He's owned this for four years, but it's struggled in the past two as they've transitioned from their hepatitis C drug era (limited growth). But they just announced great results on a new HIV drug. It's a value trap though looking cheap at 9x earnings. Pays a 3.8% dividend. They still generate lots of cash flow. He'd stick with it. At least you get that yield. Also, they just got a new CEO, so they're in transition.
Show full opinionHide full opinionHe's owned this for four years, but it's struggled in the past two as they've transitioned from their hepatitis C drug era (limited growth). But they just announced great results on a new HIV drug. It's a value trap though looking cheap at 9x earnings. Pays a 3.8% dividend. They still generate lots of cash flow. He'd stick with it. At least you get that yield. Also, they just got a new CEO, so they're in transition.
DON'T BUY
DON'T BUY
March 6, 2019
Stay away. It's a broken chart. Simple as that. Also, there will be a wall of sellers on the way up, if and when it does go up.
Show full opinionHide full opinionStay away. It's a broken chart. Simple as that. Also, there will be a wall of sellers on the way up, if and when it does go up.
HOLD
HOLD
December 21, 2018
He still likes it here and especially at these valuations. The new CEO will be good. They have announced a couple of new joint ventures and it is trading at less than 10 times earnings. Their HEP-C advantage has been declining, but they have growth in their HIV franchise.
Show full opinionHide full opinionHe still likes it here and especially at these valuations. The new CEO will be good. They have announced a couple of new joint ventures and it is trading at less than 10 times earnings. Their HEP-C advantage has been declining, but they have growth in their HIV franchise.
Gilead Sciences Inc.(GILD-Q) Rating
Ranking : 3 out of 5
Bullish - Buy Signals / Votes : 1
Neutral - Hold Signals / Votes : 1
Bearish - Sell Signals / Votes : 4
Total Signals / Votes : 6
Gilead Sciences Inc.(GILD-Q) Frequently Asked Questions
What is Gilead Sciences Inc. stock symbol?
Gilead Sciences Inc. is a American stock, trading under the symbol GILD-Q on the NASDAQ (GILD). It is usually referred to as NASDAQ:GILD or GILD-Q
Is Gilead Sciences Inc. a buy or a sell?
In the last year, 6 stock analysts published opinions about GILD-Q. 1 analyst recommended to BUY the stock. 4 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Gilead Sciences Inc..
Is Gilead Sciences Inc. a good investment or a top pick?
Gilead Sciences Inc. was recommended as a Top Pick by Shane Obata on 2020-03-20. Read the latest stock experts ratings for Gilead Sciences Inc..
Why is Gilead Sciences Inc. stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Gilead Sciences Inc. worth watching?
6 stock analysts on Stockchase covered Gilead Sciences Inc. In the last year. It is a trending stock that is worth watching.
What is Gilead Sciences Inc. stock price?
On 2020-07-07, Gilead Sciences Inc. (GILD-Q) stock closed at a price of $76.42.
